ArticleTranslational cancer research2023
Clusterin is a biomarker of breast cancer prognosis and correlated with immune microenvironment.
Article in Translational cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Drug repositioning for immunotherapy in breast cancer using single-cell analysis.NPJ systems biology and applications · 2024Pooled it
- Therapeutic strategy for cervical gastric-type adenocarcinoma by targeting CLU to relieve CLU-associated stress and sensitize chemotherapy.Precision clinical medicine · 2026Article
- Plasma clusterin levels in autism spectrum disorder: bridging biomarkers to social and cognitive dysfunctions.BMC pediatrics · 2026Article
- Detection of Biomarker Clusterin in SERS Immunoassays on Al Foil After Substrate Selection and Assay Optimization with Fluorescently Labeled Antibodies.Molecules (Basel, Switzerland) · 2025Article
- Applying integrated transcriptome and single-cell sequencing analysis to develop a prognostic signature based on M2-like tumor-associated macrophages for breast cancer.Discover oncology · 2025Article
- Clusterin facilitates glioma progression via BCL2L1-dependent regulation of apoptotic resistance.Frontiers in molecular neuroscience · 2025Article
- Clusterin ameliorates diabetic atherosclerosis by suppressing macrophage pyroptosis and activation.Frontiers in pharmacology · 2025Article
- Clusterin mediates hydroquinone-induced cytotoxic responses in HL-60 differentiated cells.Scientific reports · 2024Article
- Single-cell omics and machine learning integration to develop a polyamine metabolism-based risk score model in breast cancer patients.Journal of cancer research and clinical oncology · 2024Article
- Review
- Clusterin Is a Prognostic Biomarker of Lower-Grade Gliomas and Is Associated with Immune Cell Infiltration.International journal of molecular sciences · 2023Article
- The Ins and Outs of Clusterin: Its Role in Cancer, Eye Diseases and Wound Healing.International journal of molecular sciences · 2023Review
- miRNA deregulation and relationship with metabolic parameters after Mediterranean dietary intervention in BRCA-mutated women.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: It has been established that clusterin is involved in the invasion of immune cells in the tumor microenvironment, but it remains unknown how it promotes immune invasion in breast cancer. Methods: We used Tumor Immune Estimation Resource (TIMER) and Gene Expression Profiling Interactive Analysis (GEPIA) databases to assess the relation between expression of clusterin and immunoinfiltration-related marker genes. TIMER database was used to evaluate the expression of clusterin, and its relation to tumor immune invasion was examined. Based on Kaplan-Meier plotter database, we investigated the association between clusterin expression and prognosis in patients with cancer, and the impact of clinicopathological factors and cancer-related outcomes. Results: Clusterin expression was markedly associated with prognosis of a variety of tumors, specifically breast cancer. Enhanced clusterin expression was markedly associated with molecular typing of breast cancer and expression of multiple markers related to specific immune cell subsets. Conclusions: These results indicate that clusterin is connected to prognosis of breast cancer patients and tumor immune cell infiltration. This demonstrates that clusterin may be a biomarker of immune cell recruitment into breast tumors and an important biomarker for immune cell infiltration; consequently being a valuable prognostic factor in breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.